Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Anavex Life Sciences (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 16th, 2025, at the Westin St. Francis in San Francisco, CA, from 9:00 AM to 9:40 AM Pacific Time.
The company, which focuses on developing innovative treatments for neurological conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome, will be represented by Christopher U Missling, PhD, President & Chief Executive Officer. The presentation will be accessible via audio webcast through the Investors section of Anavex's website, with a replay available later that day.
Anavex Life Sciences (Nasdaq: AVXL), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. La presentazione avrà luogo giovedì 16 gennaio 2025, presso il Westin St. Francis a San Francisco, CA, dalle 9:00 alle 9:40 ora del Pacifico.
L'azienda, che si concentra sullo sviluppo di trattamenti innovativi per condizioni neurologiche come il morbo di Alzheimer, il morbo di Parkinson, la schizofrenia e la sindrome di Rett, sarà rappresentata da Christopher U Missling, PhD, Presidente e Amministratore Delegato. La presentazione sarà accessibile tramite webcast audio nella sezione Investitori del sito web di Anavex, con la registrazione disponibile più tardi nella giornata.
Anavex Life Sciences (Nasdaq: AVXL), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. La presentación tendrá lugar el jueves 16 de enero de 2025, en el Westin St. Francis de San Francisco, CA, de 9:00 AM a 9:40 AM hora del Pacífico.
La empresa, que se centra en desarrollar tratamientos innovadores para condiciones neurológicas como la enfermedad de Alzheimer, la enfermedad de Parkinson, la esquizofrenia y el síndrome de Rett, estará representada por Christopher U Missling, PhD, Presidente y Director Ejecutivo. La presentación será accesible a través de una transmisión de audio en la sección de Inversores del sitio web de Anavex, con una repetición disponible más tarde ese día.
Anavex Life Sciences (Nasdaq: AVXL)는 임상 단계의 생명공학 회사로서 제43회 JP모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 발표는 2025년 1월 16일 목요일에 샌프란시스코 CA의 웨스틴 세인트 프랜시스에서 태평양 표준시 기준으로 오전 9시부터 오전 9시 40분까지 진행됩니다.
이 회사는 알츠하이머병, 파킨슨병, 정신분열증, 레트 증후군 등 신경 질환에 대한 혁신적인 치료법 개발에 주력하고 있으며, Christopher U Missling 박사(사장 겸 CEO)가 대표로 참석합니다. 발표는 Anavex 웹사이트의 투자자 섹션을 통해 오디오 웨비나로 접근 가능하며, 당일 늦은 시간에 재생을 제공합니다.
Anavex Life Sciences (Nasdaq: AVXL), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. La présentation aura lieu le jeudi 16 janvier 2025, au Westin St. Francis à San Francisco, CA, de 9h00 à 9h40, heure du Pacifique.
L'entreprise, qui se concentre sur le développement de traitements innovants pour des pathologies neurologiques telles que la maladie d'Alzheimer, la maladie de Parkinson, la schizophrénie et le syndrome de Rett, sera représentée par Christopher U Missling, PhD, Président et Directeur Général. La présentation sera accessible via un webinaire audio dans la section Investisseurs du site Web d'Anavex, avec une rediffusion disponible plus tard dans la journée.
Anavex Life Sciences (Nasdaq: AVXL), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz angekündigt. Die Präsentation findet am Donnerstag, den 16. Januar 2025, im Westin St. Francis in San Francisco, CA, von 9:00 bis 9:40 Uhr pazifischer Zeit statt.
Das Unternehmen, das sich auf die Entwicklung innovativer Behandlungen für neurologische Erkrankungen wie Alzheimer, Parkinson, Schizophrenie und Rett-Syndrom konzentriert, wird von Christopher U Missling, PhD, Präsident und CEO, vertreten. Die Präsentation wird über einen Audiostream im Investorenbereich der Website von Anavex zugänglich sein, mit einer Aufzeichnung, die später am Tag verfügbar ist.
- None.
- None.
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th 2025, at the Westin St. Francis in San Francisco, CA. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 09:00 AM – 09:40 AM (Pacific Time).
An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
When is Anavex Life Sciences (AVXL) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors access AVXL's J.P. Morgan Healthcare Conference presentation?
What therapeutic areas does AVXL focus on according to the announcement?
Who will be presenting for AVXL at the 2025 J.P. Morgan Healthcare Conference?
